Cellavision Ab Stock Analysis

CellaVision Pink Sheet Analysis Notes

About 38.0% of the company shares are held by company insiders. The company last dividend was issued on the 12th of May 2022. CellaVision AB develops and sells digital solutions for blood and body fluids analysis in health care services sector in Sweden, Europe, the Middle East, Africa, the Americas, and the Asia Pacific. CellaVision AB was incorporated in 1994 and is headquartered in Lund, Sweden. Cellavision is traded on OTC Exchange in the United States.The quote for CellaVision AB is published daily by the National Quotation Bureau and the company does not need to meet minimum requirements or file with the SEC. For more info on CellaVision AB please contact Simon Ostergaard at 46 4 64 60 16 00 or go to https://www.cellavision.com.

CellaVision AB Investment Alerts

CellaVision Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 489.43 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate CellaVision's market, we take the total number of its shares issued and multiply it by CellaVision's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

CellaVision Profitablity

The company has Profit Margin (PM) of 0.19 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average.

Technical Drivers

As of the 11th of February 2026, CellaVision shows the Mean Deviation of 0.7147, risk adjusted performance of (0.09), and Standard Deviation of 2.15. CellaVision AB technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm CellaVision AB standard deviation and potential upside to decide if CellaVision AB is priced correctly, providing market reflects its regular price of 15.85 per share. Given that CellaVision has total risk alpha of (0.50), we suggest you to validate CellaVision AB's prevailing market performance to make sure the company can sustain itself at a future point.

CellaVision AB Price Movement Analysis

CellaVision Predictive Daily Indicators

CellaVision Forecast Models

CellaVision's time-series forecasting models are one of many CellaVision's pink sheet analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary CellaVision's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

CellaVision AB Debt to Cash Allocation

The company has a current ratio of 2.85, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist CellaVision until it has trouble settling it off, either with new capital or with free cash flow. So, CellaVision's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like CellaVision AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for CellaVision to invest in growth at high rates of return. When we think about CellaVision's use of debt, we should always consider it together with cash and equity.

CellaVision Assets Financed by Debt

Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the CellaVision's operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of CellaVision, which in turn will lower the firm's financial flexibility.

Pink Sheet analysis is the technique used by a trader or investor to examine and evaluate how CellaVision prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling CellaVision shares will generate the highest return on investment. We also built our pink sheet analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Pink Sheet such as CellaVision. By using and applying CellaVision Pink Sheet analysis, traders can create a robust methodology for identifying CellaVision entry and exit points for their positions.

When running CellaVision's price analysis, check to measure CellaVision's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CellaVision is operating at the current time. Most of CellaVision's value examination focuses on studying past and present price action to predict the probability of CellaVision's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CellaVision's price. Additionally, you may evaluate how the addition of CellaVision to your portfolios can decrease your overall portfolio volatility.